Alivus Life Sciences Q2FY27 Revenue Up 16% YoY to ₹6,820 Mn

Alivus Life Sciences Limited announced its financial results for the second quarter and half-year ended September 30, 2026. Revenue from operations for Q2FY27 reached ₹6,820 Mn, marking a 16.0% year-over-year growth, primarily driven by a 20.8% YoY increase in the non-GPL business. EBITDA for the quarter stood at ₹2,851 Mn, a 47.0% YoY growth, with margins at a record high of 41.8%. Profit After Tax (PAT) for Q2FY27 was ₹1,968 Mn, up 51.3% YoY. The company also reported strong free cash flow of ₹2,702 Mn, leading to cash and cash equivalents of ₹10,116 Mn. The company highlighted ongoing capacity expansion and a healthy development pipeline as key drivers for future growth.